Literature DB >> 27076600

Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care.

Brent M Egan1, Marilyn A Laken2, Susan E Sutherland3, Suparna Qanungo2, Douglas O Fleming4, Anne G Cook5, William H Hester6, Kelly W Jones6, Gerard C Jebaily6, Gregory T Valainis7, Charles F Way8, Mary Beth Wright5, Robert A Davis3.   

Abstract

BACKGROUND: Uncontrolled treatment-resistant hypertension (TRH), i.e., blood pressure (BP, mm Hg) ≥140/≥90mm Hg in and out of office on ≥3 different BP medications at optimal doses, is common and has a poor prognosis. Aldosterone antagonist (AA) and renin-guided therapy (RGT) are effective strategies for improving BP control in TRH but have not been compared.
METHODS: A comparative effectiveness TRH pilot study of AA vs. RGT was conducted in 4 primary care clinics with 2 each randomized to AA or RGT. The primary outcome was change in clinic BP defined by means of 5 automated office BP values. Eighty-nine patients with apparent TRH were screened and 44 met criteria for true TRH.
RESULTS: Baseline characteristics of 20 patients in the AA (70% Black, 45% female, mean age: 57.4 years) and 24 patients in RGT (79% Black, 50% female, 57.8 years) arms were similar with baseline BP 162±5/90±3 vs. 153±3/84±3, respectively, P = 0.11/0.20. BP declined to 144±5/86±4 in AA vs. 132±4/75±3 in RGT, P = 0.07/0.01; BP was controlled to JNC7 (Seventh Joint National Committee Report) goal in 25% vs. 62.5%, respectively, P < 0.01. Although BP changes from baseline, the primary outcome, were not different (-17.6±5.1/-4.0±3.0 AA vs. -20.4±3.8/-9.7±2.0 RGT, P = 0.65/0.10.), more BP medications were added with AA than RGT (+0.9±0.1 vs. +0.4±0.1 per patient, P < 0.01).
CONCLUSIONS: In this TRH pilot study, AA and RGT lowered BP similarly, although fewer additional medications were required with RGT. A larger comparative effectiveness study could establish the utility of these treatment strategies for lowering BP of uncontrolled TRH patients in primary care. © American Journal of Hypertension, Ltd 2016. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  aldosterone antagonists; blood pressure; clinical effectiveness; renin-guided therapy; treatment-resistant hypertension.

Mesh:

Substances:

Year:  2016        PMID: 27076600      PMCID: PMC4941594          DOI: 10.1093/ajh/hpw016

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  28 in total

1.  Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals.

Authors:  Brent M Egan; Jiexiang Li; Florence N Hutchison; Keith C Ferdinand
Journal:  Circulation       Date:  2014-10-20       Impact factor: 29.690

2.  Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy.

Authors:  Jiri Ceral; Vilma Habrdova; Viktor Vorisek; Marcel Bima; Radek Pelouch; Miroslav Solar
Journal:  Hypertens Res       Date:  2010-09-30       Impact factor: 3.872

Review 3.  Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension.

Authors:  Marilyn A Laken; Rosalind Dawson; Otis Engelman; Oscar Lovelace; Charles Way; Brent M Egan
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

Review 4.  Automated office blood pressure measurement in primary care.

Authors:  Martin G Myers; Janusz Kaczorowski; Martin Dawes; Marshall Godwin
Journal:  Can Fam Physician       Date:  2014-02       Impact factor: 3.275

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.

Authors:  Brent M Egan; Jan N Basile; Shakaib U Rehman; Phillip B Davis; Curt H Grob; Jessica Flynn Riehle; Christine A Walters; Daniel T Lackland; Carmen Merali; Jean E Sealey; John H Laragh
Journal:  Am J Hypertens       Date:  2009-04-16       Impact factor: 2.689

7.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Rationale for establishing a mechanism to increase reimbursement to hypertension specialists.

Authors:  William J Elliott; Brent Egan; Thomas D Giles; George L Bakris; William B White; Torry M Sansone
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.